NL-OMON42481已完成不适用
A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMIC EFFECTS, SAFETY AND TOLERABILITY OF REPEATED DOSING OF RO5459072 IN HEALTHY SUBJECTS - RO5459072 MAD study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male and female subjects
- •18 to 60 years old, iinclusive
- •BMI between 18.0 and 30.0 kg/m^2
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER PILOT STUDY WITH TRAMADOL TO VALIDATE TWO EXPERIMENTAL HUMAN PAIN MODELS AT THE KENDLE CLINICAL PHARMACOLOGY UNITNeuropathic pain.10034606NL-OMON32672Kendle International12
进行中（未招募）
不适用
A study to assess the effect of Aleglitazar on responsiveness (sensitivity) to insulin in patients with type 2 diabetesEUCTR2012-002649-39-DEF. Hoffmann-La Roche Ltd
进行中（未招募）
不适用
A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PERSISTENT IRRITATIVE URINARY SYMPTOMS - FI.LU.VAEUCTR2010-022138-10-ITAZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
未知
不适用
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PAHSE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF TKI258 COMBINED WITH FULVESTRANT, IN POSTMENOPAUSAL PATIENTS WITH HER-2 AND HR+ BREAST CANCER THAT HAVE EVIDENCE OF DISEASE PROGRESSION ON OR AFTER PRIOR ENDOCRINE THERAPYPER-072-12OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
不适用
A study to evaluate if Lenalidomide works in patients with myelodysplastic syndrome and with a special genetic characteristic of the disease, and who need to receive blood transfusioTransfusion-dependant, low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormalityEUCTR2005-000454-73-DECelgene Corporation135